In NSCLC, co-mutations with genetic alterations in KEAP1, SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), and CDKN2A (cyclin dependent kinase inhibitor 2A) are associated with inferior clinical outcomes to sotorasib therapy (94). The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.